Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's

BERKELEY, Calif. and MAINZ, Germany - Mainz Biomed NV (NASDAQ:MYNZ), a company focused on early cancer detection diagnostics, has announced its return to compliance with Nasdaq's stockholders' equity requirement.

Mainz Biomed NV (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements